158 related articles for article (PubMed ID: 24785004)
21. Xanthene food dye, as a modulator of Alzheimer's disease amyloid-beta peptide aggregation and the associated impaired neuronal cell function.
Wong HE; Kwon I
PLoS One; 2011; 6(10):e25752. PubMed ID: 21998691
[TBL] [Abstract][Full Text] [Related]
22. [Chronic effects of oligomeric Aβ(1-42) on hippocampal synaptic plasticity in vivo].
Tan T; Zhang BL; Tian X
Sheng Li Xue Bao; 2011 Jun; 63(3):225-32. PubMed ID: 21681340
[TBL] [Abstract][Full Text] [Related]
23. High throughput monitoring of amyloid-β(42) assembly into soluble oligomers achieved by sensitive conformation state-dependent immunoassays.
Zhao WQ; Toolan D; Hepler RW; Wolfe AL; Yu Y; Price E; Uebele VN; Schachter JB; Reynolds IJ; Renger JJ; McCampbell A; Ray WJ
J Alzheimers Dis; 2011; 25(4):655-69. PubMed ID: 21483096
[TBL] [Abstract][Full Text] [Related]
24. A new structural model of Aβ40 fibrils.
Bertini I; Gonnelli L; Luchinat C; Mao J; Nesi A
J Am Chem Soc; 2011 Oct; 133(40):16013-22. PubMed ID: 21882806
[TBL] [Abstract][Full Text] [Related]
25. Turn plasticity distinguishes different modes of amyloid-β aggregation.
Rezaei-Ghaleh N; Amininasab M; Giller K; Kumar S; Stündl A; Schneider A; Becker S; Walter J; Zweckstetter M
J Am Chem Soc; 2014 Apr; 136(13):4913-9. PubMed ID: 24617810
[TBL] [Abstract][Full Text] [Related]
26. Study of neurotoxic intracellular calcium signalling triggered by amyloids.
Villalobos C; Caballero E; Sanz-Blasco S; Núñez L
Methods Mol Biol; 2012; 849():289-302. PubMed ID: 22528098
[TBL] [Abstract][Full Text] [Related]
27. Randomization of amyloid-β-peptide(1-42) conformation by sulfonated and sulfated nanoparticles reduces aggregation and cytotoxicity.
Saraiva AM; Cardoso I; Saraiva MJ; Tauer K; Pereira MC; Coelho MA; Möhwald H; Brezesinski G
Macromol Biosci; 2010 Oct; 10(10):1152-63. PubMed ID: 20480510
[TBL] [Abstract][Full Text] [Related]
28. A2T and A2V Aβ peptides exhibit different aggregation kinetics, primary nucleation, morphology, structure, and LTP inhibition.
Murray B; Sorci M; Rosenthal J; Lippens J; Isaacson D; Das P; Fabris D; Li S; Belfort G
Proteins; 2016 Apr; 84(4):488-500. PubMed ID: 26799157
[TBL] [Abstract][Full Text] [Related]
29. Formation kinetics and structural features of Beta-amyloid aggregates by sedimented solute NMR.
Bertini I; Gallo G; Korsak M; Luchinat C; Mao J; Ravera E
Chembiochem; 2013 Sep; 14(14):1891-7. PubMed ID: 23821412
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-β₂₅₋₃₅ induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2.
Isono T; Yamashita N; Obara M; Araki T; Nakamura F; Kamiya Y; Alkam T; Nitta A; Nabeshima T; Mikoshiba K; Ohshima T; Goshima Y
Neurosci Res; 2013 Nov; 77(3):180-5. PubMed ID: 23994236
[TBL] [Abstract][Full Text] [Related]
31. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
32. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity.
Hung LW; Ciccotosto GD; Giannakis E; Tew DJ; Perez K; Masters CL; Cappai R; Wade JD; Barnham KJ
J Neurosci; 2008 Nov; 28(46):11950-8. PubMed ID: 19005060
[TBL] [Abstract][Full Text] [Related]
34. The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ
Rammes G; Parsons CG
Neuropharmacology; 2020 Nov; 179():108267. PubMed ID: 32758564
[TBL] [Abstract][Full Text] [Related]
35. The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation.
Amijee H; Bate C; Williams A; Virdee J; Jeggo R; Spanswick D; Scopes DI; Treherne JM; Mazzitelli S; Chawner R; Eyers CE; Doig AJ
Biochemistry; 2012 Oct; 51(42):8338-52. PubMed ID: 23025847
[TBL] [Abstract][Full Text] [Related]
36. Characterization of early stage intermediates in the nucleation phase of Aβ aggregation.
Zhai J; Lee TH; Small DH; Aguilar MI
Biochemistry; 2012 Feb; 51(6):1070-8. PubMed ID: 22283417
[TBL] [Abstract][Full Text] [Related]
37. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.
Matharu B; El-Agnaf O; Razvi A; Austen BM
Peptides; 2010 Oct; 31(10):1866-72. PubMed ID: 20633587
[TBL] [Abstract][Full Text] [Related]
38. In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin.
Milojevic J; Costa M; Ortiz AM; Jorquera JI; Melacini G
J Alzheimers Dis; 2014; 38(4):753-65. PubMed ID: 24072068
[TBL] [Abstract][Full Text] [Related]
39. A routine method for cloning, expressing and purifying Aβ(1-42) for structural NMR studies.
Weber DK; Sani MA; Gehman JD
Amino Acids; 2014 Oct; 46(10):2415-26. PubMed ID: 25027618
[TBL] [Abstract][Full Text] [Related]
40. Binding of human proteins to amyloid-β protofibrils.
Rahman MM; Zetterberg H; Lendel C; Härd T
ACS Chem Biol; 2015 Mar; 10(3):766-74. PubMed ID: 25469473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
